Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): Flow and endocytic mechanisms contribute to the transport

Blood

Volumn 93, Issue 5, 1999, Pages 1622-1633

  Nurden, Paquita ^a   Poujol, Christel ^b   Durrieu Jais, Catherine ^b   Winckler, Joëlle ^b   Combrié, Robert ^b   Macchi, Laurent ^b   Bihour, Claude ^b   Wagner, Carrie ^b   Jordan, Robert ^b   Nurden, Alan T ^b  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CLATHRIN; FIBRINOGEN RECEPTOR; GOLD;

ARTICLE; CELL LABELING; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENDOCYTOSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION;

EID: 0033104925     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.5.1622     Document Type: Article

References (52)

1. Wencel-Drake JD, Plow EF, Kunicki TJ, Woods VL, Keller DM, Ginsberg MH: Localization of internal pools of membrane glycoproteins involved in platelet adhesive responses. Am J Pathol 124:324, 1986
2. Cramer ER, Savidge GF, Vainchenker W, Berndt MC, Pidard D, Caen JP, Masse J-M, Breton-Gorius J: Alpha-granule pool of glycoprotein IIb-IIIa in normal and pathologic platelets and megakaryocytes. Blood 75:1220, 1990
3. Heilmann E, Hourdillé P, Pruvost A, Paponneau A, Nurden AT: Thrombin-induced platelet aggregates have a dynamic structure: Time-dependent redistribution of GP IIb-IIIa complexes and secreted adhesive proteins. Arterioscler Thromb 11:704, 1991
4. 3) to the surface membrane of human platelets during the release reaction. J Electron Microsc 43:282, 1994
5. Nurden AT, Nurden P: A review of the role of platelet membrane glycoproteins in the platelet-vessel wall interaction. Baillieres Clin Haematol 6:653, 1993
6. Nurden P: Bidirectional trafficking of membrane glycoproteins following platelet activation in suspension. Thromb Haemost 78:1305, 1997
7. Coller BS: Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics. J Clin Invest 7:1467, 1997
8. Tcheng JE, Ellis SG, George BS, Kereiakes J, Kleiman NS, Talley JD, Wzang AL, Weisman HD, Califf M, Topol EJ: Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 90:1757, 1994
9. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harrington RA, Lincoff AM, Yakubov SJ, Bray PF, Bahr RD, Wolfe CL, Yock PG, Anderson HV, Nygaard TW, Mason SJ, Effron MB, Fatterpacker A, Raskin S, Smith J, Brashear L, Gottdiener P, du Mee C, Kitt MM, Gerstenblith G: Effects of integrilin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 94:2083, 1996
10. Théroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis J-F, Nasmith J, Fung AY, Boudreault J-R, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ, on behalf of the investigators: Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban study. Circulation 94:899, 1996
11. Tcheng JE: Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 78:35, 1996
12. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb-IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956, 1994
13. George JN, Nurden AT, Phillips DR: Molecular defects in the interaction of platelets with the vessel wall. N Engl J Med 311:1094, 1984
14. Kleimann NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF: Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GP IIb-IIIa receptors. J Am Coll Cardiol 26:1665, 1995
15. Bihour C, Durrieu-Jaïs C, Macchi L, Poujol C, Coste P, Besse P, Nurden P, Nurden AT: Expression of platelet activation and the interpatient variation in response to abciximab. Arterioscler Thromb Vase Biol (in press)
16. The Capture Investigators: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 349:1429, 1997
17. Christopoulos C: Platelet surface IgG in patients receiving infusions of Fab fragments of a chimaeric monoclonal antibody to glycoprotein IIb-IIIa. Clin Exp Immunol 98:6, 1994
18. Christopoulos C, Mackie I, Lahiri A, Machin S: Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa. Blood Coagul Fibrinolysis 4:729, 1993
19. Macchi L, Clofent-Sanchez G, Marit G, Bihour C, Durrieu-Jais C, Besse P, Nurden P, Nurden AT: PAICA: A new method for characterizing platelet-associated antibodies - Its application to study of idiopathic thrombocytopenic purpura and to the detection of platelet-bound c7E3. Thromb Haemost 76:1020, 1996
20. Humbert M, Nurden P, Bihour C, Pasquet J-M, Winckler J, Heilmann E, Savi P, Herbert J-M, Kunicki TJ, Nurden AT: Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol 16:1532, 1996
21. George JN, Caen JP, Nurden AT: Glanzmann's thrombasthenia: The spectrum of clinical disease. Blood 75:1383, 1990
22. ++-binding domain. Blood 86:452a, 1995 (abstr)
23. 3 in resting and activated human platelets determined by expression of a novel class of ligand-binding sites (LIBS) recognized by monoclonal antibody, AP6. Blood 88:887, 1996
24. 3) in human platelets and megakaryocytes reveals an intracellular pool and labelling of the α-granule membrane. Br J Haematol 97:823, 1997
25. Zucker-Franklin D: Endocytosis by human platelets: Metabolic and freeze-fracture studies. J Cell Biol 91:706, 1981
26. White JG, Clawson CC: Effects of large latex particle uptake of the surface connected canalicular system of blood platelets: A freeze-fracture and cytochemical study. Ultrastruct Pathol 2:277, 1981
27. Isenberg WM, Bainton DF, Newman PJ: Monoclonal antibodies bound to subunits of the integrin GP IIb-IIIa are internalized and interfere with filopodia formation and platelet aggregation. Blood 76:1564, 1990
28. Stenberg PE, Shuman MA, Levine SP, Bainton DF. Redistribution of alpha-granules and their contents in thrombin-stimulated platelets. J Cell Biol 98:748, 1984
29. Escolar G, White JG: The platelet open canalicular system: A final common pathway. Blood Cells 17:467, 1991
30. Yeager M: Structure of cardiac gap junction intercellular channels. J Struct Biol 121:231, 1998
31. Baron V, Alengrin F, Van Obberghen E: Dynamin associates with Src-homology collagen (Shc) and becomes tyrosine phosphorylated in response to insulin. Endocrinology 139:3034, 1998
32. Escolar G, Leistikow E, White JG: The fate of the open canalicular system in surface and suspension-activated platelets. Blood 74:1983, 1989
33. Wencel-Drake JD, Boudignon-Proudhon C, Dieter MG, Criss AB, Parise LV: Internalization of bound fibrinogen modulates platelet aggregation. Blood 87:602, 1996
34. Behnke O: Coated pits and vesicles transfer plasma components to platelet granules. Thromb Haemost 62:718, 1989
35. Behnke O: Degrading and non-degrading pathways in fluid-phase (non-adsorptive) endocytosis in human blood platelets. J Submicrosc Cytol Pathol 24:169, 1992
36. Klinger MHF, Klüter H: Immunocytochemical colocalization of adhesive proteins with clathrin in human blood platelets: Further evidence for coated vesicle-mediated transport of von Willebrand factor, fibrinogen and fibronectin. Cell Tissue Res 279:453, 1995
37. Stenberg PE, Pestina TI, Barrie RJ, Jackson CW: The Src family kinases, Fgr, Fyn, Lck, and Lyn colocalize with coated membranes in platelets. Blood 89:2384, 1997
38. George JN: Platelet immunoglobulin G: Its significance for the evaluation of thrombocytopenia and for understanding the origin of α-granules. Blood 76:859, 1990
39. Santoso S, Zimmerman U, Neppert J, Mueller-Eckhardt C: Receptor patching and capping of platelet membranes induced by monoclonal antibodies. Blood 67:343, 1986
40. Morgenstern E, Ruf A, Patscheke H: Transport of antiglycoprotein Iib/IIIa-antibodies into the alpha-granules of unstimulated human blood platelets. Thromb Haemost 67:121, 1992
41. Handagama P, Bainton D, Jacques Y, Conn MT, Lazarus RA, Shuman MA: Kistrin, an integrin antagonist, blocks endocytosis of fibrinogen into guinea pig megakaryocyte and platelet α-granules. J Clin Invest 91:193, 1993
42. Wencel-Drake JD, Frelinger AL III, Dieter MG, Lam SC-T: Arg-Gly-Asp-dependent occupancy of GP IIb/IIIa by applagin: Evidence for internalization and cycling of a platelet integrin. Blood 81:62, 1993
43. Harrison P, Wilbourn B, Cramer E, Faint R, Mackie IJ, Bhattacharya S, Lahiri A, Tensa D, Machin SJ, Savidge G: The influence of therapeutic blocking of GP IIb/IIIa on platelet α-granular fibrinogen. Br J Haematol 82:721, 1992
44. Raub TJ, Denny JB, Roberts RM: Cell surface glycoproteins of CHO cells. I. Internalization and rapid recycling. Exp Cell Res 165:73, 1992
45. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE: Pharmacodynamic profile of short-term Abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb-IIIa receptor blockade. Circulation 97:1680, 1998
46. Simmon ML, Jan de Boer M, van den Brand MJBM, van Miltenburg AJM, Hoorntje JCA, Heyn drickx GR, van der Wieken LR, De Bono D, Rutsch W, Schaible TF, Weisman HF, Klootwijk P, Nijssen KM, Stibbe J, de Feyter PJ, and the European Cooperative Study Group: Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 89:596, 1994
47. Ferguson JJ: Epilog and Capture trials halted because of positive interim results. Circulation 93:637, 1996
48. Woods VL, Wolff LE, Keller DM: Resting platelets contain a substantially centrally located pool of glycoprotein IIb/IIIa complex which may be accessible to some but not other extracellular proteins. J Biol Chem 261:15242, 1986
49. Niiya K, Hodson E, Bader R, Byers-Ward V, Koziol JA, Plow EF, Ruggeri ZM: Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation. Blood 70:475, 1987
50. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RJ: Analysis of GP IIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 88:907, 1996
51. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. N Engl J Med 24:1689, 1997
52. Müller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J: Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation 96:1130, 1997